The Meals and Drug Administration (FDA) now says that 16- and 17-year olds can get a booster dose of the Pfizer-BioNTech COVID-19 vaccine.
The choice expands the company’s emergency use authorization for booster doses, which it issued on Nov. 19 for adults 18 and older. As with the earlier group, the FDA recommends that these receiving a booster ought to get the extra dose at the least six months after getting the primary two pictures of the vaccine.
The choice comes as issues concerning the Omicron variant proceed to mount, and as Pfizer-BioNTech introduced that the booster dose dramatically will increase safety in opposition to the brand new variant in comparison with the unique two doses of the vaccine. The businesses reported on Dec. 8 that in lab research, blood samples from individuals who had obtained a booster dose confirmed increased ranges of antibodies capable of neutralize the Omicron variant than samples from individuals who have been vaccinated with two doses.
[time-brightcove not-tgx=”true”]
“As individuals collect indoors with household and buddies for the vacations, we are able to’t let up on all of the preventive public well being measures that we’ve got been taking throughout the pandemic,” stated performing FDA commissioner Dr. Janet Woodcock in an announcement saying the expanded authorization. “With each the Delta and Omicron variants persevering with to unfold, vaccination stays the very best safety in opposition to COVID-19.”
In making its resolution, the FDA relied on information concerning the security and effectiveness of the extra dose for these 18 years and older, and concluded that the booster would even be protected for individuals who are 16 and 17 years outdated. The largest concern on this youthful group is the chance of irritation of coronary heart tissue related to the vaccine; the FDA scientists reviewed real-world information from vaccinated younger adults and decided that the advantages of the vaccine in defending in opposition to COVID-19 outweighed the small danger of the aspect impact.
“Since we first licensed the vaccine, new proof signifies that vaccine effectiveness in opposition to COVID-19 is waning after the second dose of the vaccine for all adults and for these within the 16- and 17-year outdated age group,” stated Dr. Peter Marks, director of the Middle for Biologics and Analysis and Analysis on the FDA, in an announcement. “A single booster dose of the vaccine for these vaccinated at the least six months prior will assist present continued safety in opposition to COVID-19 on this and older age teams.”
